Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use . The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma.

中文翻译：

---

特应性患者中的人（化）单克隆抗体 最先进的

哮喘是一种重要的慢性疾病，影响全世界许多人。如今，像生物制剂这样的哮喘治疗选择正在更加频繁地开发。尽管有很多治疗选择，一些患者仍保持症状。随着越来越多的从业者选择用生物制剂治疗作为一种方便的治疗方法，必须发现生物制剂和其他有价值的方法，以应对越来越多的治疗药物。该手稿着重介绍了在哮喘患者和标签外使用中的新一代单克隆人源化抗体。第一个开发的生物制剂是称为omalizumab的抗免疫球蛋白E单克隆抗体。目前，它是一种批准的哮喘治疗方法。